share_log

BioVaxys Announces Allowance of DPX Formulation Patent for the United States and Filing of Additional International Patent Applications for Phase 1 DPX SurMAGE

BioVaxys Announces Allowance of DPX Formulation Patent for the United States and Filing of Additional International Patent Applications for Phase 1 DPX SurMAGE

BioVaxys 宣布允许美国获得 DPX 配方专利,并针对第一阶段 DPX Surmage 提交更多国际专利申请
PR Newswire ·  04/03 20:02

VANCOUVER, B.C., April 3, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") announced that it has received a Notice of Allowance from the United States Patent and Trademark Office ("USPTO") for a Patent ("Patent") for inducing an antibody immune response from a low dose volume delivery of a B-cell epitope formulated with DPX. Part of the extensive Intellectual Property portfolio acquired by BioVaxys from the former IMV, Inc, this Patent was recently allowed in Japan and is currently pending in the European Union.

不列颠哥伦比亚省温哥华,2024年4月3日 /PRNewswire/ — BioVaxys Technology Corp.(CSE:BIOV)(FRA:5LB)(OTCQB:BVAXF)(“BioVaxys” 或 “公司”)宣布,它已收到美国专利商标局(“USPTO”)发出的诱导免疫抗体的专利(“专利”)许可通知使用DPX配制的B细胞表位的低剂量体积输送所产生的反应。该专利是BioVaxys从前IMV, Inc手中收购的广泛知识产权组合的一部分,最近在日本获得批准,目前正在欧盟待批。

DPX is a proprietary lipid-based delivery platform with no aqueous component that can be formulated with a range of packaged antigens, proteins, peptides, mRNA, or small molecules. Its unique "no release" mechanism of action allows antigen presenting cells (APCs) to be attracted to the injection site, facilitating a robust and sustained immune response.

DPX 是一种专有的基于脂质的递送平台,不含水成分,可使用一系列包装的抗原、蛋白质、肽、mRNA 或小分子配制。其独特的 “不释放” 作用机制允许抗原呈递细胞(APC)被吸引到注射部位,从而促进强大而持续的免疫反应。

The smallest dose of a currently approved vaccine is 0.1ml for Sanofi-Pasteur's Fluzone Intradermal Quadrivalent vaccine. Low dose volume delivery of DPX formulated B-cell epitope is designed to be delivered in single dose as low as 50μL to 90 μL.

目前批准的赛诺菲-巴斯德Fluzone皮内四价疫苗的最小剂量为0.1ml。DPX 配制的 B 细胞表位的低剂量体积输送设计为以低至 50μL 至 90 μL 的单剂量输送。

An epitope is the part of an antigen that the host's immune system recognizes, eliciting the immune response to an invading pathogen. It specifically binds to the corresponding antigen receptor on the immune cell (such as a B-cell). Whereas T-cells protect people from getting infected by destroying cancerous and infected cells, B-cells produce antibodies to fight infection.

表位是宿主免疫系统识别的抗原部分,可激发对入侵病原体的免疫反应。它与免疫细胞(例如B细胞)上相应的抗原受体特异性结合。T细胞通过破坏癌细胞和受感染细胞来保护人们免受感染,而B细胞则产生抗体来抵抗感染。

BioVaxys President and Chief Operating Officer Kenneth Kovan stated "Allowance of this important patent in the United States greatly expands the value of our IP and antigen delivery platform with potential partners. Having the unique ability to deliver B cell epitopes using a low dose DPX formulation is an attractive approach for packaging antigens for a range of cancer immunotherapeutics and therapeutic vaccines."

BioVaxys总裁兼首席运营官肯尼思·科文表示:“美国对这项重要专利的允许极大地扩大了我们与潜在合作伙伴的知识产权和抗原交付平台的价值。具有使用低剂量DPX配方输送B细胞表位的独特能力,是包装一系列癌症免疫疗法和治疗性疫苗抗原的一种有吸引力的方法。”

BioVaxys also is pleased to announce it has entered the national phase in the United States, Canada, European Union, Japan, and Australia with its patent application for DPX-survivin/MAGE A9 ("DPX SurMAGE"), a DPX formulation of the tumor-associated antigens survivin and MAGE A9 as a dual targeted immunotherapy.

BioVaxys还高兴地宣布,其DPX-Survivin/MAGE A9(“DPX Surmage”)(一种肿瘤相关抗原生存素的DPX配方)和作为双靶免疫疗法的MAGE A9的专利申请已进入美国、加拿大、欧盟、日本和澳大利亚的国家阶段。

The survivins and MAGE-A9 are frequently over-expressed in various human cancers including bladder, lung and kidney, and correlate with a resistance to chemotherapy and aggressiveness of tumors, and both are recognized as important targets for cancer vaccines and therapeutics.

在包括膀胱癌、肺癌和肾脏癌在内的各种人类癌症中,存活素和 MAGE-A9 经常过度表达,并与肿瘤的耐药性和侵袭性相关,两者都被认为是癌症疫苗和治疗的重要靶标。

DPX SurMAGE" recently completed a successful Phase I clinical study in Canada with bladder cancer patients conducted at CHU de Québec-Université Laval, and induced a robust peptide-specific T cell response. Kovan further added that "BioVaxys and the Phase 1 clinical study investigators see the potential with further evaluation of DPX SurMAGE, and are particularly excited by the proven ability of DPX to package multiple different antigens. We will be reconvening with the study team at CHU de Québec-Université Laval to plan further development."

DPX Surmage” 最近在加拿大成功完成了一项针对膀胱癌患者的I期临床研究,该研究在魁北克大学拉瓦尔分校进行,并诱发了强大的肽特异性T细胞反应。科文进一步补充说:“BioVaxys和1期临床研究的研究人员看到了进一步评估DPX Surmage的潜力,他们对DPX包装多种不同抗原的经过验证的能力感到特别兴奋。我们将与魁北克大学拉瓦尔分校的研究小组再次会面,以规划进一步的发展。”

About BioVaxys Technology Corp.

关于 BioVaxys 科技公司

BioVaxys Technology Corp. (), a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix 'neoantigen' tumor cell construct platform for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company's clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix 'neoantigen' tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer.

BioVaxys Technology Corp. () 是一家在加拿大不列颠哥伦比亚省注册的生物制药公司,是一家临床阶段的生物制药公司,致力于通过基于DPX免疫教育技术平台及其用于治疗癌症、传染病、抗原脱敏和其他免疫学领域的Haptenix “新抗原” 肿瘤细胞构建平台的新型免疫疗法改善患者生活。该公司的临床阶段产品线包括MaveropePimut-S,它正处于晚期复发难治性弥漫性大B细胞淋巴瘤(DLBCL)和耐铂性卵巢癌的二期临床开发,以及使用其专有的Haptenix “新抗原” 肿瘤细胞构建平台的个性化免疫治疗疫苗,该平台即将在西班牙进入I期,用于治疗屈光晚期卵巢癌。BVX-0918

The Company is also capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens.

该公司还利用其肿瘤免疫学专业知识,利用其个性化免疫治疗疫苗创建了独特的T淋巴细胞和其他数据集库,以利用预测算法和其他技术来识别新的可靶向肿瘤抗原。

BioVaxys common shares are listed on the CSE under the stock symbol "BIOV" and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF). For more information, visit and connect with us on X and LinkedIn.

BioVaxys的普通股在CSE上市,股票代码为 “BIOV”,并在法兰克福证券交易所(FRA:5LB)和美国(场外交易代码:BVAXF)上市。欲了解更多信息,请访问并通过 X 和 LinkedIn 联系我们。

ON BEHALF OF THE BOARD
Signed "James Passin"
James Passin, CEO
+1 646 452 7054

代表董事会
签名 “詹姆斯·帕森”
首席执行官詹姆斯·帕辛先生
+1 646 452 7054

SOURCE BioVaxys Technology Corp.

来源 bioVaxys 科技公司

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发